Eisai shares soared 7.4 percent as the failure of Novo Nordisk's semaglutide to reduce Alzheimer's disease progression removed a modest or perceived overhang on Biogen, which developed and co-markets Leqembi with partner Eisai.
Powered by Capital Market - Live News
a. Register on SCORES Portal (SEBI)
b. Mandatory details for filing complaints on SCORES:
i. Name, PAN, Address, Mobile Number, E-mail ID
c. Benefits:
i. Effective Communication
ii. Speedy redressal of the grievances